| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.047 | 0.3 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.02 | 0.7 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.015 | 0.8 |